Skip to main content
Frontiers in Pharmacology logoLink to Frontiers in Pharmacology
. 2026 Oct 6;17:2006892. doi: 10.3389/fphar.2026.2006892

Correction: Efficacy and safety of Nefecon, glucocorticoids, or supportive therapyadded to RASi+SGLT2i in IgA nephropathy

Tiantian Zhou 1, Hao Zhang 2, Shangchao Liu 1, Yongqiang Ji 3,*, Wei Lv 4,*
PMCID: PMC13680875  PMID: 42903499

Affiliation “School of Clinical Medicine, Shandong Second Medical University, Weifang, Shandong, China “was incorrectly written in the paper as “Clinical Medical College, Shandong Second Medical University, Weifang, Shandong, China”.

Affiliation “Yantaishan Hospital, Yantai, Shandong, China” was incorrectly written in the paper as “School of Clinical Medicine, Shandong Second Medical University, Weifang, Shandong, China”.

The original version of this article has been updated.

Footnotes

Approved by: Frontiers Editorial Office, Frontiers Media SA, Switzerland

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.


Articles from Frontiers in Pharmacology are provided here courtesy of Frontiers Media SA

RESOURCES